Related references
Note: Only part of the references are listed.Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Matrix mineralization as a trigger for osteocyte maturation
Kazuharu Irie et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2008)
Translating insights from development into regenerative medicine: The function of Wnts in bone biology
P. Leucht et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST
Mikhail V. Semenov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity
Debra L. Ellies et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
T Bellido et al.
ENDOCRINOLOGY (2005)
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor
M Semënov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
GG Loots et al.
GENOME RESEARCH (2005)
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
RL Bezooijen et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene
W Balemans et al.
BONE (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling
XF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist
RL van Bezooijen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
The natural history of sclerosteosis
H Hamersma et al.
CLINICAL GENETICS (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population
K Staehling-Hampton et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
W Balemans et al.
JOURNAL OF MEDICAL GENETICS (2002)
Dental and oral manifestations of Sclerosteosis
LXG Stephen et al.
INTERNATIONAL DENTAL JOURNAL (2001)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
ME Brunkow et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
W Balemans et al.
HUMAN MOLECULAR GENETICS (2001)
Share Paper
